Product image of Paliperidon Krka (Paliperidone) supplied by GNH India

Paliperidon Krka

Active Ingredient:
Paliperidone
Origin:
EU

Paliperidon Krka (Paliperidone)

Paliperidone, the active ingredient in Paliperidon Krka, is an atypical antipsychotic presented as a tablet for oral use. It is used to treat schizophrenia and schizoaffective disorder in adults.

GNH India supplies Paliperidon Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Krka, D.D., Novo Mesto

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Paliperidone is an atypical antipsychotic that modulates dopamine and serotonin pathways in serious mental health conditions.

  • Schizophrenia: Reduces positive and negative symptoms and helps prevent relapse.
  • Schizoaffective disorder: Improves mood symptoms and psychotic features.
  • Maintenance therapy: Supports long‑term stability after an acute episode.

How It Works

  • Paliperidone acts as an antagonist at dopamine D2 and serotonin 5‑HT2A receptors, with additional moderate affinity for α‑adrenergic and histamine H1 receptors. By blocking D2 receptors it reduces dopaminergic neurotransmission linked to psychotic symptoms, while 5‑HT2A antagonism helps balance serotonin activity, contributing to mood stabilization.

Side Effects

Paliperidone may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects

  • Akathisia: Restlessness and an urge to move constantly.
  • Weight gain: Increased appetite leading to modest weight increase.
  • Somnolence: Drowsiness or fatigue.
  • Dry mouth: Reduced salivation causing oral dryness.
  • Constipation: Slowed gastrointestinal motility.
  • Elevated prolactin: Menstrual changes or galactorrhea.

Serious or Rare Side Effects

  • Neuroleptic malignant syndrome: Potentially life‑threatening reaction with fever and muscle rigidity.
  • Tardive dyskinesia: Persistent involuntary movements.
  • Seizures: Increased risk, especially at higher doses.
  • Orthostatic hypotension: Marked blood‑pressure drop on standing.
  • Hyperglycaemia: Elevated blood‑sugar levels, may worsen diabetes.
  • Cardiac arrhythmias: QT‑interval prolongation leading to rhythm disturbances.

Precautions & Warnings

When prescribing Paliperidone, clinicians should evaluate patient history and monitor for specific safety concerns.

  • Cardiovascular assessment: Baseline ECG and periodic monitoring for QT prolongation.
  • Metabolic monitoring: Check weight, fasting glucose and lipid profile regularly.
  • Movement disorders: Observe for early signs of tardive dyskinesia or akathisia.
  • Pregnancy and lactation: Use only if benefits outweigh risks; discuss with obstetric specialist.
  • Drug‑interaction review: Assess concomitant medications that affect CYP450 enzymes.
  • Store at below 25°C: Keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Paliperidone can interact with several medicines that influence its metabolism or additive pharmacodynamic effects. Major Interactions (Avoid):\n- Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): May increase paliperidone exposure.

  • QT‑prolonging agents (e.g., sotalol, quinidine): Heighten risk of cardiac arrhythmias.
  • CNS depressants (e.g., benzodiazepines, opioids): May amplify sedation.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inducers (e.g., carbamazepine, rifampicin): May reduce paliperidone levels.
  • Antihistamines with anticholinergic properties (e.g., diphenhydramine): May worsen dry mouth.
  • Antidiabetic drugs: Monitor glucose as paliperidone can affect glycaemic control.

Frequently Asked Questions

Paliperidon Krka contains paliperidone, an atypical antipsychotic indicated for the treatment of schizophrenia and schizoaffective disorder in adults. It helps control psychotic symptoms, reduce relapses and support long‑term stability as part of a comprehensive psychiatric care plan.

Paliperidone blocks dopamine D2 receptors and serotonin 5‑HT2A receptors, decreasing dopaminergic activity that contributes to hallucinations and delusions while balancing serotonin pathways. This dual antagonism moderates mood and psychotic symptoms, providing therapeutic benefit in schizophrenia‑related disorders.

The dosage of Paliperidon Krka is individualized by the prescribing clinician based on the patient’s clinical condition, prior response, and tolerability. The prescriber determines the appropriate strength and titration schedule according to approved labeling and clinical guidelines.

Paliperidone is classified as pregnancy category C; it should be used only if the potential benefit justifies the potential risk to the fetus. Breastfeeding is not recommended because the drug is excreted in milk. Consultation with a obstetric specialist is essential before use.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Paliperidone is the primary active metabolite of risperidone and offers once‑daily oral dosing with a relatively stable pharmacokinetic profile. Compared with some older antipsychotics, it has a lower propensity for extrapyramidal symptoms but shares risks such as metabolic changes and prolactin elevation.

Store Paliperidon Krka tablets at temperatures below 25 °C in the original packaging. Protect the product from moisture, heat and direct sunlight to maintain potency throughout its shelf life.

Paliperidon Krka is supplied as oral tablets that are taken whole with water, usually once daily. It should be taken at the same time each day, with or without food, as directed by the prescribing healthcare professional.

Serious risks include neuroleptic malignant syndrome, tardive dyskinesia, significant QT‑interval prolongation, seizures and severe hyperglycaemia. Patients should be monitored regularly for cardiac, metabolic and movement‑related adverse events.

Paliperidon Krka is contraindicated in individuals with known hypersensitivity to paliperidone or any tablet excipients, and in patients with a history of severe cardiovascular disease that predisposes to QT prolongation. Caution is also advised for those with uncontrolled diabetes or a history of serious movement disorders.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Paliperidone

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT